Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on …
J Rosenstock, M Vico, LI Wei, A Salsali, JF List - Diabetes care, 2012 - Am Diabetes Assoc
OBJECTIVE To examine the safety and efficacy of dapagliflozin, a sodium-glucose
cotransporter-2 inhibitor, added on to pioglitazone in type 2 diabetes inadequately …
cotransporter-2 inhibitor, added on to pioglitazone in type 2 diabetes inadequately …
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week …
MA Nauck, S Del Prato, JJ Meier… - Diabetes …, 2011 - Am Diabetes Assoc
OBJECTIVE Although initially effective, sulfonylureas are associated with poor glycemic
durability, weight gain, and hypoglycemia. Dapagliflozin, a selective inhibitor of sodium …
durability, weight gain, and hypoglycemia. Dapagliflozin, a selective inhibitor of sodium …
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
D Müller‐Wieland, M Kellerer, K Cypryk… - Diabetes, Obesity …, 2018 - Wiley Online Library
Objective To compare the efficacy and safety of dapagliflozin and dapagliflozin plus
saxagliptin vs glimepiride as add‐on to metformin in patients with type 2 diabetes. Research …
saxagliptin vs glimepiride as add‐on to metformin in patients with type 2 diabetes. Research …
Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data
S Del Prato, M Nauck, S Duran‐Garcia… - Diabetes, Obesity …, 2015 - Wiley Online Library
Aims To assess the long‐term efficacy and tolerability of dapagliflozin versus glipizide as
add‐on to metformin in patients with inadequately controlled type 2 diabetes. Methods The …
add‐on to metformin in patients with inadequately controlled type 2 diabetes. Methods The …
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo …
K Strojek, KH Yoon, V Hruba, M Elze… - Diabetes, Obesity …, 2011 - Wiley Online Library
Aims: Progressive deterioration of glycaemic control in type 2 diabetes mellitus (T2DM) often
requires treatment intensification. Dapagliflozin increases urinary glucose excretion by …
requires treatment intensification. Dapagliflozin increases urinary glucose excretion by …
Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind …
K Strojek, KH Yoon, V Hruba, J Sugg, AM Langkilde… - Diabetes Therapy, 2014 - Springer
Introduction Maintenance of drug efficacy and safety over the long term is important to
investigate for progressive conditions like type 2 diabetes mellitus (T2DM). This study aimed …
investigate for progressive conditions like type 2 diabetes mellitus (T2DM). This study aimed …
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study
SA Jabbour, E Hardy, J Sugg, S Parikh… - Diabetes …, 2014 - Am Diabetes Assoc
OBJECTIVE To assess the efficacy and safety of dapagliflozin as add-on therapy in patients
with type 2 diabetes who were inadequately controlled with a dipeptidyl peptidase-4 …
with type 2 diabetes who were inadequately controlled with a dipeptidyl peptidase-4 …
Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo …
WT Cefalu, LA Leiter, TWA de Bruin… - Diabetes …, 2015 - Am Diabetes Assoc
OBJECTIVE To assess the efficacy and safety of dapagliflozin, a selective sodium-glucose
cotransporter 2 inhibitor, compared with placebo in patients with type 2 diabetes (T2D) …
cotransporter 2 inhibitor, compared with placebo in patients with type 2 diabetes (T2D) …
Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial
S Matthaei, K Bowering, K Rohwedder, A Grohl… - Diabetes …, 2015 - Am Diabetes Assoc
OBJECTIVE To evaluate the efficacy and safety of dapagliflozin in patients with type 2
diabetes inadequately controlled with metformin and sulfonylurea. RESEARCH DESIGN …
diabetes inadequately controlled with metformin and sulfonylurea. RESEARCH DESIGN …
A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment
JPH Wilding, P Norwood, C T'joen, A Bastien… - Diabetes …, 2009 - Am Diabetes Assoc
OBJECTIVE To determine whether dapagliflozin, which selectively inhibits renal glucose
reabsorption, lowers hyperglycemia in patients with type 2 diabetes that is poorly controlled …
reabsorption, lowers hyperglycemia in patients with type 2 diabetes that is poorly controlled …
相关搜索
- hypoglycemia risk effects of dapagliflozin
- hypoglycemia risk pioglitazone monotherapy
- hypoglycemia risk sglt2 inhibitor
- body weight effects of dapagliflozin
- pioglitazone monotherapy effects of dapagliflozin
- sglt2 inhibitor effects of dapagliflozin
- 24 week effect of dapagliflozin
- body weight glycemic control
- pioglitazone monotherapy sglt2 inhibitor
- dapagliflozin monotherapy diabetic patients
- metformin in patients safety of dapagliflozin
- high doses dapagliflozin in patients
- insulin sensitizers dapagliflozin in patients
- glimepiride in patients weight loss
- diabetes mellitus weight loss
- dapagliflozin monotherapy diet and exercise